Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

As we work to adjust to our new normal during COVID-19, now more than ever, staying fracture-free is critical for anyone with osteoporosis. Healthcare systems are over-stretched, with general recommendations […]

On behalf of Osteoporosis Canada’s Scientific Advisory Consultants and Osteoporosis Canada, we would like to announce this year’s Lindy Fraser Award winner as chosen by the members of the SAC. […]

It is well known that calcium is a necessary nutrient because it plays an essential role in human health, not only for bone development but also for the heart, muscle […]

Take action to make sure you are staying fracture-free and are taking care of your bone health. This pandemic has put enormous pressure on our healthcare systems stretching our resources […]

The B.C. Ministry of Health is conducting a survey of patients, caregivers, and advocacy groups to achieve input regarding osteoporosis therapies in British Columbia and B.C. PharmaCare coverage. We know […]

A recent study from the US suggests women who drink as little as one cup /250 ml of cow’s milk per day could be increasing their risk of developing breast […]